Sign In
to Vote &
Create Storyboards.
 

35% Upside Likely For Nektar Therapeutics?

Forbes - 6 Jan 2021 15:00
35% Upside Likely For Nektar Therapeutics? We believe that Nektar Therapeutics stock, a biopharmaceutical company focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain, is a good buying opportunity at the present time. NKTR stock trades near $18 currently and it is, in fact...
3
0
0


Storyboard
Print
Share this Article



Comment on this Article

Please Sign In to comment

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard